Table 3.
Concentration (μg/ml) | Log EC50 (M) | Emax (%) | |||||
---|---|---|---|---|---|---|---|
ACh | NTG | 5-HT | ACh | NTG | 5-HT | ||
Control | 0 | −6.1 (− 6.3 to − 5.8) | − 6.6 (− 7.0 to − 5.7) | − 5.3 (− 5.5 to − 5.2) | 42.9 (38.7–48.6) | 78.3 (66.7–113.2) | 115.8 (105.1–127.5) |
E171 | 14 | −5.9 (− 6.1 to − 5.7) | − 6.9 (− 7.1 to − 6.6) | − 5.4 (− 5.6 to − 5.2) | 56.3* (52.5–61.3) | 65.3 (59.9–73.5) | 148.5* (131.3–168.2) |
140 | −6.1 (− 6.4 to − 5.6) | − 7.1 (− 7.4 to − 6.7) | − 5.3 (− 5.5 to − 5.1) | 44.9 (38.9–55.2) | 67.2 (60.4–79.3) | 172.7* (151.4–197.3) | |
Aeroxide P25 | 14 | −6.1 (− 6.4 to − 5.8) | −6.9 (− 7.3 to − 6.1) | − 5.3 (− 5.6 to − 5.1) | 45.9 (41.8–51.8) | 70.8 (61.0–98.8) | 130.6 (111.3–152.5) |
140 | −5.7 (− 6.0 to − 5.3) | − 6.8 (− 7.0 to − 6.6) | −5.4 (− 5.5 to − 5.3) | 42.4 (37.7–51.4) | 80.5 (73.7–91.3) | 122.5 (114.0–131.4) | |
E153 | 10 | −6.0 (− 6.2 to − 5.7) | −6.8 (− 7.1 to − 6.2) | −5.4 (− 5.7 to − 5.1) | 50.4 (45.9–57.5) | 61.0 (53.3–79.6) | 147.0 (122.7–179.5) |
100 | −5.9 (− 6.1 to − 5.7) | − 6.7 (− 7.3 to 0.2) | −5.1 (− 5.3 to − 4.9) | 57.5* (52.7–64.6) | 84.1 (67.5–514.0) | 143.4 (125.7–166.5) | |
Printex 90 | 10 | −6.1 (− 6.7 to − 2.1) | −6.0 (− 6.5 to − 3.4) | − 5.3 (ND to − 5.2) | 48.7 (39.3–161.2) | 68.7 (53.0–188.8) | 147.1* (134.8–160.0) |
100 | −6.0 (− 6.3 to − 5.6) | −6.4 (− 6.8 to − 5.6) | −5.3 (− 5.5 to − 5.2) | 50.8 (45.3–59.3) | 75.6 (63.9–109.5) | 123.6 (112.5–135.4) |
The concentration-response curves were performed for acetylcholine (ACh), nitroglycerine (NTG) and 5-hydroxytryptamine (5-HT) on aorta from rats exposed ex vivo to E171, Aeroxide P25, E153 or Printex 90 for 30 min. The data are presented as the mean and 95% CI. The number of animals in each group varied; specified in Figs. 3, 4 and 5. Asterisk (*) denotes statistically significant effects on Emax when compared to the effect in the control group (P < 0.05), ND: the value could not be determined by non-linear regression analysis